Dr. Agustin A Garcia M.D.
Oncologist | Medical Oncology
52579 HIGHWAY 51 S INDEPENDENCE LA, 70443About
Dr. Agustin Garcia is an oncologist practicing in Los Angeles, CA. Dr. Garcia specializes in the care and treatment of patients with cancer. As an oncologist, Dr. Garcia manages and oversees the treatment of a cancer patient after he or she has been diagnosed with the disease. Oncologists will care for their patients throughout the course of the disease. Types of oncologists include medical oncologists, surgical oncologists, radiation oncologists, gynecologic oncologists, pediatric oncologists and hematologist oncologists.
Education and Training
Universidad Anahuac Escuela De Medicina, Mexico MD
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
- Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
- Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
- Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
- Update on aromatase inhibitors in breast cancer.
- Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.
- Bevacizumab in the management of solid tumors.
- Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
- Current status of signal transduction modulators in the treatment of gynecologic malignancies.
- Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
- Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
- Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
- Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Dr. Agustin A Garcia M.D.'s Practice location
INDEPENDENCE, LA 70443Get Direction
Dr. Agustin A Garcia M.D.'s reviews
Write ReviewPatient Experience with Dr. Garcia
Recommended Articles
- What Are Lymphocytes? Low, Normal, and High Lymphocyte Counts
Lymphocytes are a type of white blood cell produced in the bone marrow. A few lymphocytes enter the bloodstream while some move into the lymphatic system. Having a low or high lymphocyte count can help identify a person's medical condition. Normal lymphocyte counts usually vary from one laboratory...
- Actress Mindy Cohn Reveals 5-Year Fight Against Breast Cancer
Many may remember her as the dark-haired girl in the popular 80s sitcom, The Facts of Life. On screen, she can be seen portraying the woe and trials of being a teenager.More than 30 years later, she shares with the public that she's been enduring a much harder battle in her life. In 2012, Mindy was...
- New Screening Method Can Detect Tumor-Derived DNA in Women with Early Ovarian Cancer
Diagnostic issues have plagued ovarian cancer treatment efforts. Physical symptoms of ovarian cancer are initially vague (primarily mild common gastric and urinary problems). Surgical biopsy is its primary diagnostic focus.Scientists have relied on DNA alterations found in biopsied tumor samples to...
- What OB-GYNs Wish Their Patients Knew about Ovarian Cancer
There are numerous things OB-GYN providers want their patients to know about ovarian cancer.For instance, that it is somewhat rare, but deadly. It ranks 5th in cancer deaths among women. Due primarily to the diagnostic issues noted below, about 70% of women are unfortunately in the most advanced...
- Breast Cancer Death Rate Has Dropped Dramatically in the US
The results from a 2015 breast cancer study are in, and the news is great!The study shows there is a 39% lower death rate in the US from breast cancer. And that there has been a steady decline of such deaths since 1989. The reduction in breast cancer-related deaths is reported to be the result of...
- Can High Blood Pressure Benefit Those with Ovarian Cancer?
Ovarian cancer is the most fatal of all reproductive cancers that women face. Fewer than half of the women diagnosed with ovarian cancer will survive more than five years after their diagnosis, leading to over 152,000 deaths each and every year. Cancer research programs are constantly trying to find...